PATENT CLAIM ANALYSIS

Application Number: 15988414
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["514", "045000"]

Abstract:
The present invention relates to a composition comprising a first compound which is a nucleoside analogue capable of inhibiting a bacterial colonisation or infection of a subject; a second compound which is capable of decreasing mitochondrial toxicity of said nucleoside analogue and surprisingly enhance the antibacterial effect of the combination; and a third compound capable of decreasing the concentration in bacteria of nucleosides and/or nucleotides known to compete with nucleoside analogues. The first compound may be AZT, FdUrd, 5-fluorouracil, BrdUrd, IdUrd, didanosine or gemcitabine; the second compound may be uridine or a uridine-comprising compound; and the third compound may be iclaprim; trimethoprim; or a compound comprising trimethoprim, such as trimethoprim-sulfa.

Claim (Index 3):
The method according to  claim 1 , wherein the combined antibacterial effect of the nucleoside analogue, iclaprim and the second compound is greater than the sum of the effect provided if administered separately and the toxicity is reduced.

Metadata:
- Claim Count in Document: 45.0
- Percentile: 93.0
- Lexical Diversity: 1.9375
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14943555', '10933628', '08460186', '14560097', '14000682']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7171314609205366
- 35 USC 102 Novelty (BERT): 0.5064183936157177
- Combined Prediction Score: 0.6960601541900547
- Mean Citation Score: 195.377268
- Max Citation Score: 210.19371
- Similarity Product: 138.64779686068476

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test